Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ELOXATIN vs AKTOB
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Oxaliplatin undergoes non-enzymatic biotransformation to form platinum-DNA adducts, leading to inhibition of DNA replication and transcription, and ultimately cell death. It is a third-generation platinum-based alkylating agent.
Immunosuppressant; inhibits T-cell activation by binding to cyclophilin and inhibiting calcineurin, thereby blocking IL-2 transcription.
Adjuvant treatment of stage III colon cancer after complete resection of primary tumor,Treatment of advanced colorectal cancer in combination with 5-fluorouracil and leucovorin
Prevention of organ rejection in kidney, liver, and heart transplants,Rheumatoid arthritis,Psoriasis
85 mg/m2 IV over 2 hours on day 1, repeated every 2 weeks (adjuvant); 85 mg/m2 IV over 2 hours on day 1, repeated every 2 weeks or 130 mg/m2 IV over 2 hours on day 1, repeated every 3 weeks (advanced disease).
Adults: 10 mg orally once daily.
Terminal half-life of ultrafilterable platinum: ~10-27 hours (mean ~14 hours); total platinum: ~40-50 hours. Clinical context: prolonged exposure due to tissue binding.
Terminal elimination half-life is 8-12 hours; prolonged in renal impairment (up to 20-30 hours in anuria).
Oxaliplatin undergoes rapid non-enzymatic biotransformation in plasma and tissues to form active platinum derivatives, primarily via displacement of the oxalate ligand. Minimal hepatic metabolism; elimination is predominantly renal.
Hepatic via CYP3A4 enzyme system; major metabolites include AM1, AM9, and AM4N.
Renal: ~54% of platinum excreted in urine within 48 hours; fecal: small amount (<2%); biliary excretion is minimal.
Renal: 70-80% unchanged; biliary/fecal: 10-15% as metabolites.
Platinum binds >90% to plasma proteins, mainly albumin and gamma-globulins; irreversible binding.
20-30% primarily to albumin.
Vd of ultrafilterable platinum: ~0.4-0.6 L/kg; total platinum: ~4-6 L/kg, indicating extensive tissue distribution.
0.25-0.4 L/kg; indicates distribution primarily in extracellular fluid.
Oral: Not bioavailable (unstable in GI tract); IV: 100%.
Intramuscular: approximately 90%; oral: not absorbed (0% due to degradation in GI tract).
Cr Cl ≥60 m L/min: No adjustment; Cr Cl 50-59 m L/min: No adjustment; Cr Cl 40-49 m L/min: Administer 85 mg/m2, but no data for 130 mg/m2; Cr Cl 30-39 m L/min: Administer 85 mg/m2 with caution, no data for 130 mg/m2; Cr Cl 20-29 m L/min: Administer 85 mg/m2 with extreme caution, no data for 130 mg/m2; Cr Cl <20 m L/min: Not recommended.
GFR 30-89 m L/min: no adjustment; GFR 15-29 m L/min: 5 mg once daily; GFR <15 m L/min or dialysis: 2.5 mg once daily.
Child-Pugh A: No adjustment required; Child-Pugh B: No adjustment required; Child-Pugh C: Use with caution; no specific dose reduction defined.
Child-Pugh A: no adjustment; Child-Pugh B: 5 mg once daily; Child-Pugh C: not recommended.
Not approved for pediatric use. No established dosing guidelines.
Not established for children <18 years.
No specific dose adjustment recommended based on age alone; monitor renal function and adjust according to calculated creatinine clearance.
No specific dose adjustment; monitor for hypotension and renal function.
Anaphylactic-like reactions to oxaliplatin have been reported, which may occur within minutes of administration and require immediate discontinuation and symptomatic treatment. Oxaliplatin should be discontinued if severe hypersensitivity occurs.
Increased risk of lymphomas and other malignancies, particularly of the skin. Increased susceptibility to infections. Cyclosporine can cause nephrotoxicity and hepatotoxicity.
Hypersensitivity reactions (including anaphylaxis) have been reported and may be life-threatening. Discontinue permanently if severe reaction occurs.,Peripheral neuropathy, which may be acute (reversible) or chronic (persistent), is dose-limiting and requires dose adjustment or discontinuation.,Hepatotoxicity, including hepatic sinusoidal obstruction syndrome, has been reported. Monitor liver function.,Pulmonary toxicity, including pulmonary fibrosis, has been observed. Discontinue if interstitial lung disease is suspected.,Bleeding risk due to thrombocytopenia; monitor platelet counts.,Rhabdomyolysis has been reported; monitor for muscle pain/weakness.,Post-marketing reports of reversible posterior leukoencephalopathy syndrome (RPLS); discontinue if symptoms occur.
Nephrotoxicity, hepatotoxicity, hypertension, hyperkalemia, neurotoxicity, increased risk of infections and malignancies, anaphylaxis (IV formulation).
History of severe hypersensitivity to oxaliplatin or any components of the formulation,Severe renal impairment (creatinine clearance <30 m L/min),Bone marrow suppression with baseline neutrophil count <1.5 × 10^9/L or platelet count <75 × 10^9/L,Pregnancy (can cause fetal harm)
Hypersensitivity to cyclosporine or any component of the formulation, abnormal renal function, uncontrolled hypertension, malignancies, concurrent use with PUVA or UVB therapy in psoriasis.
Avoid cold food and beverages for 48 hours post-infusion to prevent acute neuropathy exacerbation. No known specific food-drug interactions; however, avoid grapefruit juice if taking CYP3A4-metabolized drugs (not oxaliplatin itself). Maintain adequate hydration; no restriction with normal meals.
No significant food interactions. Avoid alcohol while taking this medication.
Eloxatin (oxaliplatin) is a platinum-based antineoplastic agent classified as FDA Pregnancy Category D. There is evidence of fetal harm based on animal studies and its mechanism of action (DNA cross-linking). Use during pregnancy is contraindicated unless maternal benefit outweighs risk. First trimester exposure carries highest risk of major malformations; second and third trimester exposure may cause fetal growth restriction, myelosuppression, and neurotoxicity.
First trimester: Limited human data; animal studies show adverse effects at high doses. Avoid unless benefit outweighs risk. Second/third trimester: No documented teratogenicity; monitor for fetal growth restriction and oligohydramnios.
It is unknown whether oxaliplatin or its metabolites are excreted in human milk. Due to potential serious adverse reactions in nursing infants, including myelosuppression and neurotoxicity, breastfeeding is not recommended during treatment and for at least 3 months after the last dose. No M/P ratio data available.
Not recommended during breastfeeding. M/P ratio unknown; potential infant exposure via milk.
No established dosing adjustments for pregnancy. Physiological changes (increased volume of distribution, altered hepatic metabolism, enhanced renal clearance) may reduce drug exposure. However, due to teratogenicity, use is not recommended. If deemed necessary, therapeutic drug monitoring is not standard and dose adjustments should be made based on clinical response and toxicity, with cautious monitoring of side effects.
No standard dose adjustment; increased clearance in pregnancy may require higher doses; therapeutic drug monitoring advised.
Eloxatin (oxaliplatin) causes acute and chronic peripheral neuropathy; acute symptoms are triggered by cold exposure. Premedicate with antiemetics (e.g., aprepitant, dexamethasone, 5-HT3 antagonist) and avoid cold drinks or ice during infusion and for 48 hours thereafter. Monitor for laryngopharyngeal dysesthesia with cold exposure. Do not use aluminum-containing needles or IV sets as they degrade platinum compounds. Oxaliplatin is not compatible with chloride-containing solutions; dilute only in 5% dextrose in water. Assess renal function and reduce dose if Cr Cl < 30 m L/min.
AKTOB is a beta-lactam antibiotic; monitor for hypersensitivity reactions, especially in patients with penicillin allergy. Adjust dose in renal impairment (Cr Cl <30 m L/min). Administer by slow IV infusion over 3-5 minutes or as directed. Observe for signs of Clostridioides difficile infection.
Avoid cold drinks, ice, and cold temperatures during and for 2 days after infusion to prevent severe tingling or throat discomfort.,Report any numbness, tingling, or pain in hands/feet that interferes with daily activities or does not improve between cycles.,Take anti-nausea medications as prescribed before each infusion; call your doctor if vomiting persists.,Watch for signs of allergic reaction: rash, hives, difficulty breathing, swelling of face/lips/tongue.,Do not touch infusion tubing or eat ice chips during treatment due to cold sensitivity.
Complete the full course of therapy even if symptoms improve.,Report any signs of allergic reaction such as rash, itching, or difficulty breathing immediately.,Inform your doctor if you have kidney problems or are on dialysis.,This medication may cause diarrhea; do not treat with anti-diarrheal medications without consulting your doctor.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ELOXATIN vs AKTOB, answered by our medical review team.
ELOXATIN is a Platinum-Based Antineoplastic that works by Oxaliplatin undergoes non-enzymatic biotransformation to form platinum-DNA adducts, leading to inhibition of DNA replication and transcription, and ultimately cell death. It is a third-generation platinum-based alkylating agent.. AKTOB is a Aminoglycoside Antibiotic (Ophthalmic) that works by Immunosuppressant; inhibits T-cell activation by binding to cyclophilin and inhibiting calcineurin, thereby blocking IL-2 transcription.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ELOXATIN and AKTOB depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ELOXATIN is: 85 mg/m2 IV over 2 hours on day 1, repeated every 2 weeks (adjuvant); 85 mg/m2 IV over 2 hours on day 1, repeated every 2 weeks or 130 mg/m2 IV over 2 hours on day 1, repeated every 3 weeks (advanced disease).. The standard adult dose of AKTOB is: Adults: 10 mg orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ELOXATIN and AKTOB in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ELOXATIN is classified as Category C. Eloxatin (oxaliplatin) is a platinum-based antineoplastic agent classified as FDA Pregnancy Category D. There is evidence of fetal harm based on animal studies and its mechanism of. AKTOB is classified as Category C. First trimester: Limited human data; animal studies show adverse effects at high doses. Avoid unless benefit outweighs risk. Second/third trimester: No documented teratogenicity; m. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.